Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
drug effect requires functioning beta cells (Type 1 diabetics have few functioning beta cells, and beta cells numbers can also decline over time in type 2 diabetes) Indications: type II diabetes a drug of choice for patients where metformin is contraindicated (or who cannot tolerate metformin) can be added in combination with other hypoglycemic drugs or insulin Contraindications: type I diabetes (where patients lack pancreatic -cells) Use with caution in patients with significant hepatic impairment (due to a high risk for hypoglycemia)
It has antimicrobial and anti-inflammatory properties, making it suitable for use in dermatology (Table 10)
The compound has never received market authorization in Canada or anywhere else, and Metabolic Pharmaceuticals terminated clinical development in 2007 after the Phase IIb obesity trial failed
In TCA group, median disease duration was 4 years with IQR of 26 years while in the methoxsalen group, median disease duration was 5 years with IQR of 17 years
US$ 1195.00
Sold : Login>>
